Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITⅡ: Short-Course Radiotherapy Combined With mFOLFOX6, PD-1 Antibody and Cetuximab/Bevacizumab in High-Risk pMMR/MSS Rectal Adenocarcinoma
NCT07549399Phase 3Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- May 2026
- Primary completion
- Apr 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of PD-1 Monoclonal Antibody, cetuximab, bevacizumab in rectal adenocarcinoma, sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Started May 2026; status: recruiting.
02
Drugs
PD-1 Monoclonal Antibodycetuximabbevacizumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT07549399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549399.